Lorlatinib is approved in the US and in Europe for the second- or third-line treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC). Reference standards of Lorlatinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Lorlatinib
Catalogue No.:PA 12 1490000
CAS :
Molecular Formula : C21H19FN6O2
Molecular Weight : 406.42
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
